Profile data is unavailable for this security.
About the company
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
- Revenue in USD (TTM)4.70m
- Net income in USD-79.58m
- Incorporated1989
- Employees66.00
- LocationArmata Pharmaceuticals Inc5005 Mcconnell AveLOS ANGELES 90066United StatesUSA
- Phone+1 (310) 665-2928
- Fax+1 (310) 665-2963
- Websitehttps://www.armatapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanopharmaceutics Inc | 1.01m | -549.47k | 104.40m | 50.00 | -- | -- | -- | 103.41 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -65.10m | 104.94m | 63.00 | -- | 0.4935 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Allakos Inc | 0.00 | -214.44m | 106.25m | 131.00 | -- | 1.01 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 106.38m | 54.00 | -- | 1.18 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -94.30m | 106.51m | 20.00 | -- | 1.48 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 108.10m | 93.00 | -- | 2.61 | -- | 21.89 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 111.76m | 66.00 | -- | -- | -- | 23.78 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Immunic Inc | 0.00 | -97.92m | 114.40m | 77.00 | -- | 1.37 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| FibroGen Inc | 167.49m | -240.46m | 115.39m | 486.00 | -- | -- | -- | 0.6889 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 116.49m | 405.00 | -- | 2.02 | -- | 6.21 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 116.63m | 56.00 | -- | 1.37 | -- | 198.35 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 116.65m | 168.00 | -- | 0.7702 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 117.57m | 13.00 | -- | 9.14 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 118.10m | 37.00 | -- | 0.958 | -- | 113.31 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 118.45m | 18.00 | -- | 2.32 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 119.35m | 384.00 | -- | 0.3677 | -- | 0.2999 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
Data as of May 11 2024. Currency figures normalised to Armata Pharmaceuticals Inc's reporting currency: US Dollar USD
3.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 633.95k | 1.75% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 141.11k | 0.39% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 110.38k | 0.31% |
| Geode Capital Management LLCas of 31 Dec 2023 | 101.01k | 0.28% |
| Edgewood Management LLCas of 31 Dec 2023 | 100.00k | 0.28% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 53.60k | 0.15% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 40.30k | 0.11% |
| SeaCrest Wealth Management LLCas of 31 Mar 2024 | 32.78k | 0.09% |
| Qube Research & Technologies Ltd.as of 31 Dec 2023 | 23.56k | 0.07% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 20.76k | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
